Hamdi AKAN, Selami KOÇAK TOPRAK, Erden ATİLLA, Meral BEKSAÇ, Pervin TOPÇUOĞLU, Muhit ÖZCAN, Pınar ATACA ATİLLA, Günhan GÜRMAN, Osman İLHAN, Ekin KIRCALI, Taner DEMİRER, Önder ARSLAN

Tüylü Hücreli Lösemide Tedavi Yaklaşımımız

Amaç: Tüylü hücreli lösemi (THL), olgun B hücrelerinden kaynaklanan, nadir görülen bir kronik lenfoid malignitedir. Tüm lösemiler içindeki sıklığı %2olup, hastalar çoğunlukla orta yaşlarda tanı almaktadır. Pürin analogları hastalık tedavisinde kullanılır. Bu çalışmada amacımız THL hastalarımızındemografik özelliklerini, aldıkları tedavileri ve tedaviye cevaplarını sunmaktır.Gereç ve Yöntem: 1984-2019 yılları arasında merkezimizde teşhis ve tedavi edilen 38 THL hastası geriye dönük olarak incelenmiştir. Karşılaştırmalardaki-kare testi ve student t testi kullanılmıştır. P

Our Treatment Approach to Hairy Cell Leukemia

Objectives: Hairy cell leukemia (HCL) is a rare chronic lymphoid malignancy which develops from mature B cells. The frequency is 2% of all leukemias and diagnosed mostly in middle ages. Patients respond to treatment with purine analogues. In this study, our aim is to present our HCL patients, their demographic features, treatment modalities and response to therapy. Materials and Methods: Thirty-eight HCL patients who were diagnosed and treated at our center between 1984 and 2019 were retrospectively evaluated. Ki-square test and student t-test were used in comparison. P

PDF

___

1. Shao H, Calvo KR, Grönborg M, et al. Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria. Leuk Res 2013;37:401-409.
2. Zakarija A, Peterson LC, Tallman MS. Hairy Cell Leukemia. In: Hoffman R, editor. Hematology, Basic Principles and Practice. Churchill-Livingstone- Elsevier; 2009.
3. Frassoldati A, Lamparelli T, Federico M, et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma 1994;13:307- 316.
4. Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl 2):50-52.
5. Foucar K, Falini B, Catovsky D, et al. Hairy cell leukaemia. World Healthn Organization Classification of Tumors of Haematopoietics and Lymphoid Tissues. In: Swerdlow SH, Campo E, Harris NL, et al editors. IARC Press, Lyon; 2008. p. 180-190.
6. Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129:553-560.
7. Rai K. Consensus resolution: Proposed criteria for evaluation of response to treatment in hairy cell leukemia. Leukemia. 1987;1:405.
8. Piris MA, Foucar K, Mollejo M, et al. Splenic B-cell lymphoma/leukaemia, unclassifiable. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC; 2008. p. 191-193.
9. Pettirossi V, Santi A, Imperi E, et al. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood. 2015;125:1207-1216.
10. Andrulis M, Penzel R, Weichert W, et al. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012;36:1796-1800.
11. Cannon T, Mobarek D, Wegge J, et al. Hairy cell leukemia: current concepts. Cancer Invest. 2008;26:860-865.
12. Cornet E, Delmer A, Feugier P, et al. French Society of Haematology. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia. Ann Hematol. 2014;93:1977-1983.
13. Seymour JF, Kurzrock R, Freireich EJ, et al. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients withhairy cell leukemia. Blood. 1994;83:2906-2911.
14. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007;109:3672-3675.
15. Gedik E, Girgin S, Aldemir M, et al. Non-traumatic splenic rupture: report of seven cases and review of the literature. World J Gastroenterol. 2008;14:6711-6716.
16. Habermann TM, Rai K. Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses. Leuk Lymphoma. 2011;52(Suppl 2):18-20.
17. Daver N, Nazha A, Kantarjian HM, et al. Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. Clinl Lymphoma Myeloma Leuk. 2013;13:86-89.
18. Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective studyof 238 patients. Leukemia. 2003;17:45-51.